Original Research
Published on 07 Nov 2025
Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)
in Pharmacology of Anti-Cancer Drugs
Original Research
Published on 07 Nov 2025
in Pharmacology of Anti-Cancer Drugs
Editorial
Published on 07 Nov 2025
in Molecular and Cellular Pathology
Original Research
Published on 07 Nov 2025
in Cancer Immunity and Immunotherapy
Original Research
Published on 07 Nov 2025
in Surgical Oncology
Original Research
Published on 07 Nov 2025
in Neurotrauma
Editorial
Published on 07 Nov 2025
in Environmental Economics and Management
Original Research
Published on 07 Nov 2025
in Pediatric Cardiology
Original Research
Published on 07 Nov 2025
in Sports Management, Marketing, and Economics
Review
Published on 07 Nov 2025
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Hypothesis and Theory
Published on 07 Nov 2025
in Public Mental Health
Correction
Published on 07 Nov 2025
in Exercise Physiology
Original Research
Accepted on 06 Nov 2025
in Microbiotechnology
Editorial
Accepted on 06 Nov 2025
in Psychopharmacology
Study Protocol
Accepted on 06 Nov 2025
in Schizophrenia
Case Report
Accepted on 06 Nov 2025
in Pediatric Infectious Diseases
Original Research
Accepted on 06 Nov 2025
in Cancer Immunity and Immunotherapy